Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings from a phase 2 trial in ... has shown a clinical benefit in ...

The EC approved Libtayo – a fully human monoclonal antibody ... chat with the Grove.AI team about their new AI agent for clinical trial recruitment. Join the conversation, on Tuesday 28th ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

This news follows a recent Phase 3 trial where Keytruda®, another immunotherapy, failed to show similar benefits in the same setting. The success of Libtayo in this trial could represent a significant ...